Associated Papers
Mutation of Epigenetic Regulators at Diagnosis Is an Independent Predictor of Tyrosine Kinase Inhibitor Treatment Failure in Chronic Myeloid Leukemia: A Report From the RESIDIAG Study.
Guerineau H et al.
American Journal of Hematology, 2025
39654506 (PubMed )
Supplement: supplement_1.pdf
Human HDAC6 senses valine abundancy to regulate DNA damage.
Jin J et al.
Nature, 2025
Poor Applicability of Currently Available Prognostic Scoring Systems for Prediction of Outcome in KIT D816V-Negative Advanced Systemic Mastocytosis.
Naumann N et al.
Cancers, 2024
TET2 is required to suppress mTORC1 signaling through urea cycle with therapeutic potential.
He J et al.
Cell Discovery, 2023
TET2 Suppresses VHL Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling.
Zhang X et al.
Cancer Research, 2022
Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy.
Xu YP et al.
The Journal of Clinical Investigation, 2019
Convenient expression, purification and quantitative liquid chromatography-tandem mass spectrometry-based analysis of TET2 5-methylcytosine demethylase.
Jaiswal M et al.
Protein Expression and Purification, 2017
Fumarate and Succinate Regulate Expression of Hypoxia-inducible Genes via TET Enzymes.
Laukka T et al.
The Journal of Biological Chemistry, 2016
Evaluation of allelic strength of human TET2 mutations and cooperation between Tet2 knockdown and oncogenic Nras mutation.
Chang YI et al.
British Journal of Haematology, 2014
Feature-based classification of amino acid substitutions outside conserved functional protein domains.
Gemovic B et al.
Thescientificworldjournal, 2013
24348198 (PubMed )
Supplement: 948617.f1.pdf
Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.
Ko M et al.
Nature, 2010
Acquired mutations in TET2 are common in myelodysplastic syndromes.
Langemeijer SM et al.
Nature Genetics, 2009
Targeted next-generation sequencing-based sequencing of cell-free DNA in cerebrospinal fluid uncovers cancer-specific mutations in patients with brain cancer using a widely available panel.
Köpp A et al.
Neuro-oncology Advances, 0
41664825 (PubMed )
Supplement: vdaf270_supplementary_data.zip › Table_S2.xlsx › Variants_Blood_and_CSF
Select a paper to view details